Developing a first-in-class, localized immunotherapy to

MAKE CANCER DRUGS WORK BETTER FOR PATIENTS WITH SOLID TUMORS

Revolutionizing solid tumor treatment with AIM-001

Allo-Immunotherapy (AIM-001): A New Era in Localized Immunotherapy

Key features of AIM-001

Solid Tumors

Broad application across solid tumor types and disease stages. 

Bait the immune system

AIM-001 induces the transplant rejection immune response at the site of the tumor.

Solve the puzzle

AIM-001 makes checkpoint immunotherapy work better for more patients. Turns cold tumors hot.

Ease of use

Localized delivery of AIM-001 during biopsy or tumor resection surgery. 

PEOPLE HAVE CANCER GLOBALLY 🡪 90M WITH SOLID TUMORS
0 M
OF SOLID TUMOR PATIENTS DO NOT RESPOND TO CHECKPOINT IMMUNOTHERAPY
0 %
INCREASE IN NEW CANCER CASES & CANCER RELATED DEATHS BY 2040
0 %
YEAR SURVIVAL RATES FOR DIFFICULT-TO-TREAT TUMORS REMAIN STAGNANT
0

OUR TECHNOLOGIES

problem we solve

Improve outcomes for patients with advanced solid tumors and limited therapeutic options. Help checkpoint immunotherapy portfolios work better for more patients. Majority of patients do not respond to checkpoint immunotherapy – AIM-001 unlocks the potential.

our solution

AIM-001 is simple, localized cell-based therapy implanted at the primary or metastatic tumor site during biopsy or resection surgery. AIM-001 baits the immune system locally and activates the immune system systemically to sensitize patients to checkpoint immunotherapy, resulting in increased response rates, durability, and expanded patient eligibility.

THE AIM-001 ADVANTAGE:

Contact Info

Follow us

GET IN TOUCH

Our Trusted Partners